Results from a large, randomised clinical trial for patients with breast cancer show that those who received bevacizumab (Avastin) in combination with paclitaxel (Taxol) survived without the disease getting worse for almost twice as long as patients who received paclitaxel alone. The results were announced today at the 5th European Breast Cancer Conference (EBCC-5).

A total of 722 patients with locally recurrent or metastatic breast cancer were enrolled in the study. Patients were randomised into two treatment groups. One group received the standard treatment, paclitaxel alone and the second group received the new drug combination of paclitaxel with bevacizumab. Researchers found that patients who received bevacizumab in combination with paclitaxel had significantly improved progression free survival of 11.4 months, compared to 6.11 months with paclitaxel alone - a statistically significant difference. Initial overall survival data is also promising and shows a trend towards improved overall survival (28.4 vs 25.2 months) with the new drug combination.

"These results are good news for people with breast cancer," said the study author Dr. R. Zon, Michiana Hematology Oncology, P.C. USA, adding, "A drug with a novel mode of action on the blood vessels within the cancer has not added side effects for patients and those who received the test drugs kept their cancer under control for almost twice as long as patients who received the standard regimen. The next step will be introducing the new drug in patients whose breast cancer has not progressed to metastasis."

The clinical trial was sponsored by the National Cancer Institute (NCI) and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG), one of the largest clinical cancer research organisations in the U.S. The promising trial results showed only a minimal increase in toxicity when bevacizumab was added to paclitaxel. Manageable side effects of the drug comb
'"/>

Contact: EBCC-5 Press Office
stephanie.makin@toniclc.com
33-49-392-8402
Federation of European Cancer Societies
22-Mar-2006

Page: 1 2
Related biology news :

1. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
2. Jefferson researchers develop combined procedure for uterine preservation in treating fibroids
3. High HPV concentrations combined with smoking significantly raise risks of cervical cancer
4. Study provides first-ever look at combined causes of North Atlantic and Arctic Ocean freshening
5. Vaccine combined with short-term postexposure antibiotics protects monkeys from inhalational anthrax
6. Cholesterol-lowering foods most effective when combined, U of T study
7. Biologists see combined structure of cold virus and receptor molecule
8. Saturated fats combined with genetic trait implicated in development of type 2 diabetes
9. Timing is everything for optimum combined cancer therapy
10. Encouraging results of gene therapy for severe combined immunodeficiency
11. Resveratrol prolongs lifespan and delays onset of aging-related traits in a short-lived vertebrate